In this work, we analyzed 28 studies conducted from 1989 to 2021, studying 37 genetic variations, including SNVs/polymorphisms of four candidate dopamine receptor genes (DRD1, DRD2, DRD3, DRD4) involved in the development of AIP and AITD in patients with schizophrenia. This evidence concerns the gene DRD1 and schizophrenia.